What is Design Therapeutics, Inc.'s stock issuance proceeds?

Design Therapeutics, Inc. (DSGN) reported stock issuance proceeds of $19.91M in Q1 2026.

What is the long-term trend for Design Therapeutics, Inc.'s stock issuance proceeds?

Over 2 years (2022 to 2025), Design Therapeutics, Inc.'s stock issuance proceeds has grown at a 777.1% compound annual growth rate (CAGR), from $323K to $24.85M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Design Therapeutics, Inc. DSGN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

ALN

Alnylam PharmaceuticalsALNY

$13.16M-73.3%

Intellia TherapeuticsNTLA

$194.6M—

CRISPR TherapeuticsCRSP

-$722K-108%

Dyne Therapeutics, Inc.DYN

$0-100%

Taysha Gene Therapies, Inc.TSHA

$516K+588%

Sarepta Therapeutics, Inc.SRPT

$241K-98.5%

Other financials

Income statement

See full

Revenue-—

Operating income-$19.7M+3.5%

Net income-$17.6M+0.4%

EPS (diluted)-$0.29+6.5%

Balance sheet

See full

Cash & equivalents$12.8M-6.6%

Total debt$2.7M+27.7%

Total equity$218.1M-4.3%

Total assets$230.4M-3.0%

Cash flow

See full

Operating cash flow-$16.4M+2.1%

CapEx--100%

Free cash flow-$16.4M+2.6%

Valuation

See full

Market cap$860.66M+305%

Enterprise value$850.62M+324%

Profitability

See full

Operating margin-3,685.8%—

Net margin-3,663.7%—

Returns & leverage

See full

Return on equity-31.3%+19.5pp

Debt / equity0×0.0×

Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Design Therapeutics, Inc.'s stock issuance proceeds?: Design Therapeutics, Inc. (DSGN) reported stock issuance proceeds of $19.91M in Q1 2026.
What is the long-term trend for Design Therapeutics, Inc.'s stock issuance proceeds?: Over 2 years (2022 to 2025), Design Therapeutics, Inc.'s stock issuance proceeds has grown at a 777.1% compound annual growth rate (CAGR), from $323K to $24.85M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.